The current landscape of m6A modification in urological cancers.
Bladder cancer
Epigenetic modifications
N6-methyladenosine
Prostate cancer
Renal cell carcinoma
Urological cancer
Journal
PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
04
2023
accepted:
11
08
2023
medline:
14
9
2023
pubmed:
13
9
2023
entrez:
13
9
2023
Statut:
epublish
Résumé
N6-methyladenosine (m6A) methylation is a dynamic and reversible procession of epigenetic modifications. It is increasingly recognized that m6A modification has been involved in the tumorigenesis, development, and progression of urological tumors. Emerging research explored the role of m6A modification in urological cancer. In this review, we will summarize the relationship between m6A modification, renal cell carcinoma, bladder cancer, and prostate cancer, and discover the biological function of m6A regulators in tumor cells. We will also discuss the possible mechanism and future application value used as a potential biomarker or therapeutic target to benefit patients with urological cancers.
Identifiants
pubmed: 37701836
doi: 10.7717/peerj.16023
pii: 16023
pmc: PMC10493088
doi:
Substances chimiques
Adenosine
K72T3FS567
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16023Informations de copyright
©2023 Zeng et al.
Déclaration de conflit d'intérêts
The authors declare there are no competing interests.
Références
Cancer Treat Rev. 2018 Nov;70:127-137
pubmed: 30173085
Mol Oncol. 2022 May;16(9):1841-1856
pubmed: 35048498
Front Immunol. 2022 Sep 15;13:1014861
pubmed: 36189296
Epigenomics. 2020 Jan;12(2):87-99
pubmed: 31856595
Theranostics. 2022 Aug 29;12(14):6291-6307
pubmed: 36168624
Cancer Res. 2021 Feb 15;81(4):923-934
pubmed: 33293428
Clin Transl Med. 2021 Feb;11(2):e310
pubmed: 33634966
Front Oncol. 2022 Jun 22;12:914692
pubmed: 35814454
Cancers (Basel). 2020 Mar 25;12(4):
pubmed: 32218194
Front Oncol. 2021 Mar 16;11:598017
pubmed: 33796449
Cell Biol Toxicol. 2021 Dec;37(6):811-831
pubmed: 34272618
Life Sci. 2021 Aug 1;278:119565
pubmed: 33965380
Mol Carcinog. 2021 May;60(5):354-362
pubmed: 33755994
Cancer Res. 2021 May 1;81(9):2259-2269
pubmed: 33509939
Nucleic Acids Res. 2022 Jan 7;50(D1):D231-D235
pubmed: 34893873
Theranostics. 2021 Jun 11;11(16):7640-7657
pubmed: 34335955
J Cancer. 2021 Jan 1;12(3):682-692
pubmed: 33403026
Nat Rev Clin Oncol. 2021 Oct;18(10):663-672
pubmed: 34079102
Cell Death Discov. 2022 Apr 13;8(1):199
pubmed: 35418191
Arch Toxicol. 2021 Jan;95(1):299-309
pubmed: 32964246
Exp Hematol Oncol. 2022 Aug 9;11(1):45
pubmed: 35945641
J Exp Clin Cancer Res. 2021 Aug 25;40(1):268
pubmed: 34446080
PeerJ. 2020 Mar 18;8:e8827
pubmed: 32219036
Mol Cell. 2019 May 16;74(4):640-650
pubmed: 31100245
Genomics. 2022 Jul;114(4):110424
pubmed: 35798250
Mol Cancer. 2020 Oct 29;19(1):152
pubmed: 33121495
Front Genet. 2022 Jan 21;12:795611
pubmed: 35126463
Cell Death Dis. 2023 Apr 24;14(4):289
pubmed: 37095108
Life Sci. 2021 Apr 15;271:119180
pubmed: 33571513
Stem Cells Int. 2020 Jul 2;2020:8849218
pubmed: 32676121
J Cancer. 2020 Mar 25;11(12):3588-3595
pubmed: 32284755
Cell. 2015 Jun 4;161(6):1388-99
pubmed: 26046440
Front Genet. 2022 Sep 06;13:1007696
pubmed: 36171885
Cancer Gene Ther. 2023 Jan;30(1):209-218
pubmed: 36195720
Oncogene. 2019 May;38(19):3667-3680
pubmed: 30659266
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33574053
Front Immunol. 2021 Oct 18;12:722642
pubmed: 34733275
Cancer Cell Int. 2021 Dec 19;21(1):680
pubmed: 34923969
Front Genet. 2021 Nov 26;12:768041
pubmed: 34899855
Front Cell Dev Biol. 2021 Sep 23;9:737498
pubmed: 34631715
Front Pharmacol. 2021 Aug 27;12:709548
pubmed: 34512342
Front Cell Dev Biol. 2021 Feb 18;9:627706
pubmed: 33681207
J Cell Mol Med. 2019 Mar;23(3):2163-2173
pubmed: 30648791
Clin Cancer Res. 2017 Apr 15;23(8):1886-1890
pubmed: 27903674
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Cell Int. 2020 May 07;20:157
pubmed: 32419773
J Cell Mol Med. 2020 Apr;24(7):4092-4104
pubmed: 32126149
Cell Res. 2018 May;28(5):507-517
pubmed: 29686311
Mol Cancer. 2022 Jan 12;21(1):14
pubmed: 35022030
Front Genet. 2021 May 28;12:609174
pubmed: 34122497
Cancer Cell Int. 2022 Feb 11;22(1):72
pubmed: 35148766
Mol Cancer. 2022 May 10;21(1):111
pubmed: 35538475
Proc Natl Acad Sci U S A. 2020 Sep 1;117(35):21441-21449
pubmed: 32817424
Transl Oncol. 2022 Nov;25:101518
pubmed: 36037557
Oncogene. 2019 Jun;38(24):4755-4772
pubmed: 30796352
J Cell Mol Med. 2020 Oct;24(19):11366-11380
pubmed: 32857912
J Med Chem. 2021 Sep 9;64(17):12738-12760
pubmed: 34431664
Oncogene. 2019 Aug;38(34):6211-6225
pubmed: 31289360
Nat Rev Mol Cell Biol. 2019 Oct;20(10):608-624
pubmed: 31520073
BJU Int. 2020 Apr;125(4):617-624
pubmed: 31985880
Mol Cancer. 2022 Jul 15;21(1):146
pubmed: 35840930
Transl Androl Urol. 2021 Feb;10(2):662-679
pubmed: 33718069
Cell Death Discov. 2022 Mar 30;8(1):143
pubmed: 35354789
Mol Cancer. 2022 Jan 18;21(1):23
pubmed: 35042525
Proc Natl Acad Sci U S A. 1974 Oct;71(10):3971-5
pubmed: 4372599
Cancer Sci. 2022 Feb;113(2):446-458
pubmed: 34813676
Front Oncol. 2021 Mar 18;11:642159
pubmed: 33816290
Nature. 2019 Jul;571(7766):489-499
pubmed: 31341302
Cell Res. 2014 Feb;24(2):177-89
pubmed: 24407421
Int J Biol Sci. 2022 Oct 3;18(15):5943-5962
pubmed: 36263177
Mol Med Rep. 2022 Sep;26(3):
pubmed: 35856412
Clin Transl Med. 2022 Jun;12(6):e906
pubmed: 35678231
J Transl Med. 2022 Jul 6;20(1):298
pubmed: 35794583
Cell Death Discov. 2022 Aug 12;8(1):356
pubmed: 35961973
J Hematol Oncol. 2021 Mar 19;14(1):46
pubmed: 33741027
Front Med (Lausanne). 2021 Dec 23;8:757432
pubmed: 35004726
Nucleic Acids Res. 1975 Oct;2(10):1653-68
pubmed: 1187339
Nat Rev Cancer. 2020 Jun;20(6):303-322
pubmed: 32300195
Int J Mol Sci. 2023 Apr 07;24(8):
pubmed: 37108067
Front Oncol. 2021 Jul 06;11:709579
pubmed: 34295828
Cancer Med. 2021 Nov;10(21):7804-7815
pubmed: 34668652
Science. 2018 Sep 28;361(6409):1346-1349
pubmed: 30262497
Cell Transplant. 2022 Jan-Dec;31:9636897221122997
pubmed: 36073002
Front Oncol. 2020 Sep 23;10:1566
pubmed: 33102202
Nature. 2012 Apr 29;485(7397):201-6
pubmed: 22575960
Cell Death Discov. 2022 Apr 9;8(1):184
pubmed: 35397614
Clin Transl Med. 2021 Jun;11(6):e426
pubmed: 34185427
Cell Death Discov. 2021 Nov 1;7(1):329
pubmed: 34725345
Front Oncol. 2022 Mar 02;12:820242
pubmed: 35311150
Front Cell Dev Biol. 2021 Jan 21;8:616972
pubmed: 33553151
Cell Death Dis. 2023 Jan 25;14(1):59
pubmed: 36697384
Mol Cancer. 2019 Jun 22;18(1):110
pubmed: 31228940
Theranostics. 2021 Jan 26;11(8):3676-3693
pubmed: 33664855
J Immunol Res. 2021 Feb 12;2021:6617841
pubmed: 33628845
Front Oncol. 2022 Jun 02;12:895315
pubmed: 35719976
Front Immunol. 2022 Jun 17;13:818120
pubmed: 35784363
Cancer Med. 2021 Oct;10(20):7222-7232
pubmed: 34595849
Cancer Commun (Lond). 2023 Apr;43(4):480-502
pubmed: 36860124
Front Genet. 2022 Apr 26;13:831162
pubmed: 35559023
Front Oncol. 2021 Nov 15;11:717622
pubmed: 34868913
Cancers (Basel). 2022 Aug 21;14(16):
pubmed: 36011028
J Pers Med. 2021 Sep 30;11(10):
pubmed: 34683137
Cell Death Dis. 2021 Jul 29;12(8):750
pubmed: 34326314
Mol Cancer. 2019 Nov 25;18(1):168
pubmed: 31760940
Cancer Cell Int. 2022 Jan 19;22(1):33
pubmed: 35045837
Signal Transduct Target Ther. 2021 Dec 20;6(1):422
pubmed: 34924561
Biomed Res Int. 2021 Feb 6;2021:4582082
pubmed: 33628782
Mol Cancer. 2021 Apr 14;20(1):68
pubmed: 33853613
Mol Immunol. 2021 Sep;137:28-40
pubmed: 34186454
EBioMedicine. 2019 Sep;47:195-207
pubmed: 31409574
J Cancer. 2021 Apr 24;12(12):3575-3586
pubmed: 33995635
Cell. 2017 Jun 15;169(7):1187-1200
pubmed: 28622506
Mol Cell. 2016 May 5;62(3):335-345
pubmed: 27117702
Front Oncol. 2021 Sep 15;11:714267
pubmed: 34604051
J Hematol Oncol. 2019 Nov 22;12(1):121
pubmed: 31757221
Front Oncol. 2020 Jan 24;10:3
pubmed: 32038982
Front Genet. 2022 Jan 11;12:825109
pubmed: 35087575
Nat Rev Mol Cell Biol. 2021 Jun;22(6):375-392
pubmed: 33658722